Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

Bone Marrow Transplantation, Published online: 09 March 2024; doi:10.1038/s41409-024-02202-9Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

Source: Bone Marrow Transplantation - March 9, 2024 Category: Hematology Authors: Thomas Longval Anne-Claire Lepr être Aur élie Ravinet Amandine Fayard Edouard Forcade Tereza Coman Rabah Redjoul Ana Berceanu Nimrod Buchbinder Guillaume Berlie Maria Mappoura Federica Giannotti Florian Chevillon Marie Robin R égis Peffault de Latour F Source Type: research